These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21439785)

  • 21. PI3Kδ drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation.
    Haylock-Jacobs S; Comerford I; Bunting M; Kara E; Townley S; Klingler-Hoffmann M; Vanhaesebroeck B; Puri KD; McColl SR
    J Autoimmun; 2011 May; 36(3-4):278-87. PubMed ID: 21396797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PETIR-001, a dual inhibitor of dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN), ameliorates experimental autoimmune encephalomyelitis in SJL/J mice.
    Reinhold D; Bank U; Entz D; Goihl A; Stoye D; Wrenger S; Brocke S; Thielitz A; Stefin S; Nordhoff K; Heimburg A; Täger M; Ansorge S
    Biol Chem; 2011 Mar; 392(3):233-7. PubMed ID: 21194377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and validation of gene therapies in autoimmune diseases: Epidemiology to animal models.
    Leung PS; Shu SA; Kenny TP; Wu PY; Tao MH
    Autoimmun Rev; 2010 Mar; 9(5):A400-5. PubMed ID: 20035901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of intracellular cathepsin activities and suppression of immune responses mediated by helper T lymphocyte type-2 by peroral or intraperitoneal administration of vitamin B6.
    Katunuma N; Matsui A; Endo K; Hanba J; Sato A; Nakano M; Yuto Y; Tada Y; Asao T; Himeno K; Maekawa Y; Inubushi T
    Biochem Biophys Res Commun; 2000 May; 272(1):151-5. PubMed ID: 10872819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exposure to T helper 2 cytokines in vivo before encounter with antigen selects for T helper subsets via alterations in antigen-presenting cell function.
    Cua DJ; Coffman RL; Stohlman SA
    J Immunol; 1996 Oct; 157(7):2830-6. PubMed ID: 8816386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram.
    Ross SE; Williams RO; Mason LJ; Mauri C; Marinova-Mutafchieva L; Malfait AM; Maini RN; Feldmann M
    J Immunol; 1997 Dec; 159(12):6253-9. PubMed ID: 9550429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exacerbation of autoimmune arthritis by copolymer-I through promoting type 1 immune response and autoantibody production.
    Zheng B; Switzer K; Marinova E; Zhang J; Han S
    Autoimmunity; 2008 Aug; 41(5):363-71. PubMed ID: 18568641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation.
    Fissolo N; Kraus M; Reich M; Ayturan M; Overkleeft H; Driessen C; Weissert R
    Eur J Immunol; 2008 Sep; 38(9):2401-11. PubMed ID: 18792018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of molecular imaging to quantify response to IKK-2 inhibitor treatment in murine arthritis.
    Izmailova ES; Paz N; Alencar H; Chun M; Schopf L; Hepperle M; Lane JH; Harriman G; Xu Y; Ocain T; Weissleder R; Mahmood U; Healy AM; Jaffee B
    Arthritis Rheum; 2007 Jan; 56(1):117-28. PubMed ID: 17195214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteoglycan (aggrecan)-induced arthritis in BALB/c mice is a Th1-type disease regulated by Th2 cytokines.
    Finnegan A; Mikecz K; Tao P; Glant TT
    J Immunol; 1999 Nov; 163(10):5383-90. PubMed ID: 10553063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of IL-12 in the induction of organ-specific autoimmune diseases.
    Trembleau S; Germann T; Gately MK; Adorini L
    Immunol Today; 1995 Aug; 16(8):383-6. PubMed ID: 7546194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spinal cathepsin S and fractalkine contribute to chronic pain in the collagen-induced arthritis model.
    Clark AK; Grist J; Al-Kashi A; Perretti M; Malcangio M
    Arthritis Rheum; 2012 Jun; 64(6):2038-47. PubMed ID: 22213084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The gap-junction inhibitor carbenoxolone suppresses the differentiation of Th17 cells through inhibition of IL-23 expression in antigen presenting cells.
    Endong L; Shijie J; Sonobe Y; Di M; Hua L; Kawanokuchi J; Mizuno T; Suzumura A
    J Neuroimmunol; 2011 Dec; 240-241():58-64. PubMed ID: 22036952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease.
    Jahagirdar R; Attwell S; Marusic S; Bendele A; Shenoy N; McLure KG; Gilham D; Norek K; Hansen HC; Yu R; Tobin J; Wagner GS; Young PR; Wong NCW; Kulikowski E
    Mol Pharmacol; 2017 Dec; 92(6):694-706. PubMed ID: 28974538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases.
    Van Rompaey L; Galien R; van der Aar EM; Clement-Lacroix P; Nelles L; Smets B; Lepescheux L; Christophe T; Conrath K; Vandeghinste N; Vayssiere B; De Vos S; Fletcher S; Brys R; van 't Klooster G; Feyen JH; Menet C
    J Immunol; 2013 Oct; 191(7):3568-77. PubMed ID: 24006460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential benefit of the cathepsin S inhibitor, ASP1617, as a treatment for systemic lupus erythematosus.
    Kawato Y; Fukahori H; Nakamura K; Kanno A; Kubo K; Hiramitsu M; Matsuda T; Hanada Y; Furukawa T; Nakajima Y; Kinugasa F; Morokata T
    Eur J Pharmacol; 2022 Mar; 919():174826. PubMed ID: 35157914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis of proline analogues as potent and selective cathepsin S inhibitors.
    Kim M; Jeon J; Song J; Suh KH; Kim YH; Min KH; Lee KO
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3140-4. PubMed ID: 23639544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins.
    Lider O; Baharav E; Mekori YA; Miller T; Naparstek Y; Vlodavsky I; Cohen IR
    J Clin Invest; 1989 Mar; 83(3):752-6. PubMed ID: 2493485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of orally administered rapamycin in animal models of arthritis and other autoimmune diseases.
    Carlson RP; Baeder WL; Caccese RG; Warner LM; Sehgal SN
    Ann N Y Acad Sci; 1993 Jun; 685():86-113. PubMed ID: 8363289
    [No Abstract]   [Full Text] [Related]  

  • 40. Design of biodegradable nanoparticles to modulate phenotypes of antigen-presenting cells for antigen-specific treatment of autoimmune disease.
    Saito E; Kuo R; Kramer KR; Gohel N; Giles DA; Moore BB; Miller SD; Shea LD
    Biomaterials; 2019 Nov; 222():119432. PubMed ID: 31480002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.